Pregabalin

Generic Name
Pregabalin
Brand Names
Lyrica, Pregabalin Accord, Pregabalin Pfizer, Pregabalin Sandoz, Pregabalin Mylan, Pregabalin Zentiva
Drug Type
Small Molecule
Chemical Formula
C8H17NO2
CAS Number
148553-50-8
Unique Ingredient Identifier
55JG375S6M
Background

Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by bind...

Indication

Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.

Associated Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Epilepsies, Fibromyalgia, Generalized Anxiety Disorder, Neuropathic Pain, Partial-Onset Seizures, Peripheral Neuropathic Pain, Peripheral neuropathy, Postherpetic Neuralgia
Associated Therapies
-
Clinical Trials
Related News

Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial

Phase 4
Terminated
Conditions
Partial Seizures
Interventions
Drug: Pregabalin
First Posted Date
2006-12-05
Last Posted Date
2021-01-25
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
136
Registration Number
NCT00407797
Locations
🇲🇽

Pfizer Investigational Site, Estado de México, Mexico

A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

Phase 3
Completed
Conditions
Neuralgia
Spinal Cord Injuries
Interventions
Drug: placebo
Drug: pregabalin
First Posted Date
2006-12-05
Last Posted Date
2021-01-25
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
220
Registration Number
NCT00407745
Locations
🇷🇺

Pfizer Investigational Site, St.Petersburg, Russian Federation

Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP

First Posted Date
2006-12-05
Last Posted Date
2021-02-09
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
121
Registration Number
NCT00407511
Locations
🇻🇪

Pfizer Investigational Site, Caracas, Distrito Capital, Venezuela

Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia

First Posted Date
2006-11-27
Last Posted Date
2018-06-15
Lead Sponsor
Karolinska Institutet
Target Recruit Count
18
Registration Number
NCT00403780
Locations
🇸🇪

Department of Vascular Surgery, Karolinska University Hospital, Stockholm, Sweden

🇸🇪

Deptartment of Vascular Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden

🇸🇪

Deptartment of Surgery, South Hospital, Stockholm, Sweden

A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia

Phase 3
Completed
Conditions
Neuralgia, Postherpetic
Interventions
Drug: Placebo
Drug: Pregabalin
First Posted Date
2006-11-02
Last Posted Date
2021-02-09
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
372
Registration Number
NCT00394901
Locations
🇯🇵

Pfizer Investigational Site, Saitama, Japan

An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain

First Posted Date
2006-10-11
Last Posted Date
2011-07-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
407
Registration Number
NCT00385671
Locations
🇩🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany

A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer

First Posted Date
2006-09-27
Last Posted Date
2021-01-20
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
152
Registration Number
NCT00381095
Locations
🇻🇪

Pfizer Investigational Site, Caracas, Distrito Capital, Venezuela

Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer

First Posted Date
2006-09-27
Last Posted Date
2021-02-11
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
64
Registration Number
NCT00380874
Locations
🇨🇳

Pfizer Investigational Site, Taipei, Taiwan

Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

First Posted Date
2006-09-01
Last Posted Date
2011-03-16
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
318
Registration Number
NCT00371033
Locations
🇺🇸

Charles R Drew University of Medicine & Science, Los Angeles, California, United States

🇨🇦

Queen's University, Kingston, Ontario, Canada

🇺🇸

University of Mississippi Medical Center, Jackson, Mississippi, United States

and more 8 locations

Effects of Pregabalin, Duloxetine & Amitriptyline on Pain & Sleep

First Posted Date
2006-09-01
Last Posted Date
2009-11-17
Lead Sponsor
University of Surrey
Target Recruit Count
90
Registration Number
NCT00370656
Locations
🇬🇧

Poole General Hospital, Poole, Dorset, United Kingdom

🇬🇧

Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom

🇬🇧

University of Surrey Clinical Research Centre, Guildford, Surrey, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy